ipratropium bromide + salbutamol at a glance
Medicine class
Short-acting beta2 agonist plus short-acting muscarinic antagonist bronchodilator.
Licensed role
Management of bronchospasm in COPD when both components are required regularly.
Administration
Inhaled through a suitable nebuliser; it must not be swallowed or injected.
Protect the eyes
Keep nebuliser mist away from the eyes, particularly if narrow-angle glaucoma is a risk.
What is ipratropium bromide + salbutamol used for?
The selected UK product is licensed for:
Bronchospasm in people with COPD who require regular treatment with both ipratropium and salbutamol.
How does ipratropium bromide + salbutamol work?
Ipratropium blocks muscarinic receptors involved in airway narrowing. Salbutamol stimulates beta2 receptors to relax airway smooth muscle. Their complementary actions produce greater bronchodilation than either component alone.
How to take ipratropium bromide + salbutamol
Use only with a suitable nebuliser as instructed by a healthcare professional and the device manufacturer.
Open a fresh single-use vial immediately before use and transfer the instructed contents into the nebuliser chamber.
Do not use an open, damaged or discoloured vial.
Discard any solution left after administration.
Do not mix it with another medicine unless specifically directed.
Use a well-fitting mouthpiece or mask and keep the mist out of the eyes.
Clean the nebuliser according to its manufacturer’s instructions.
ipratropium bromide + salbutamol side effects
Common or expected effects
- Headache or dizziness
- Feeling shaky or nervous
- Faster heartbeat or palpitations
- Cough, throat irritation or voice changes
- Dry mouth
- Nausea
- Skin reactions
Get urgent medical advice
- Sudden worsening of wheeze or breathlessness after inhalation
- Swelling of the face, lips, tongue or throat, severe rash, faintness or breathing difficulty
- Painful red eye, blurred vision or coloured halos
- Persistent fast or irregular heartbeat, chest pain or severe dizziness
- Muscle weakness, cramps or an irregular heartbeat suggesting low potassium
- Difficulty passing urine, particularly with existing urinary outflow obstruction
ipratropium bromide + salbutamol in pregnancy
Use during pregnancy, particularly in the first trimester, is recommended only when the expected benefit outweighs possible fetal risk. Discuss treatment with the respiratory and maternity teams rather than stopping it without advice.
ipratropium bromide + salbutamol while breastfeeding
Treatment during breastfeeding is recommended only when the expected benefit outweighs possible risk to the baby. Review the need for this combination with the prescriber, especially for a premature or unwell infant.
ipratropium bromide + salbutamol interactions
Tell the prescriber and pharmacist about all medicines, including inhalers and non-prescription products.
Beta blockers
They can substantially reduce salbutamol’s bronchodilator effect and may worsen bronchospasm.
Other beta agonists or xanthines
They may increase bronchodilation, tremor, palpitations and other adverse effects.
Corticosteroids, xanthines and potassium-lowering diuretics
They may increase the risk of low potassium, particularly during severe airway obstruction or hypoxia.
Common questions about ipratropium bromide + salbutamol
Answers are fully visible for fast scanning and source review.
What is ipratropium bromide + salbutamol used for?
The selected UK product is licensed for bronchospasm in COPD when regular treatment with both bronchodilators is needed.
Is it licensed for asthma?
Not in the selected UK product information; its licensed indication is COPD-associated bronchospasm requiring both components.
Can it be mixed with other nebuliser medicines?
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.